RELX-INTERNATIONAL
RELX International, a responsible multinational electronic cigarettes company, is continuing its support for the Hashemite Kingdom of Jordan to adopt a more favourable fiscal policy when it comes to the country’s e-cigarette polices and taxes. Should policies and taxes on these products be revised in line with regional markets such as Egypt, Kuwait, Saudi Arabia and the UAE, Jordanian adult smokers, the business environment and government financial reserves will benefit greatly.
According to the Jordan National Stepwise Survey (STEPs) for Noncommunicable Diseases Risk Factors 2019, adult smokers in Jordan smoke an average of 21.3 cigarettes a day [1]. The rate is said to be amongst the highest in the world, with worldwide scientific research linking high tobacco use to a raft of diseases. In contrast, an increasing number of reputed organisations including the UK’s National Health Service (NHS) has said that e-cigarettes are far less harmful than traditional cigarettes, and can actually help smokers reduce or quit smoking altogether [2].
For adult smokers in Jordan, reforming e-cigarette policies and reducing taxes will bring legal access to accessibly priced, premium quality e-cigarette products, which are backed by the latest research & development. Responsible brands will also be able to work closer with their partners to educate adult consumers about the risks and benefits of their products, and restrict access to minors. Consumers can also rest assured that regulated products have been signed off by the Jordanian Food and Drug Administration, which is the sole national competent authority for drug safety & efficacy and food safety & quality.
While e-cigarette products do contain nicotine and so are not completely without risks, the latter is not the main cause of smoking-related diseases according to various regulatory and health organisations including the aforementioned NHS. In fact, a research paper published on the website ‘Tobacco Control’ has stated that the replacement of combustible cigarettes by e-cigarettes use over a 10-year period yields 6.6-million fewer premature deaths, with 86.7-million fewer life years lost in the Optimistic Scenario in the United States alone [3].
Apart from the benefit to adult smokers in the country, broad e-cigarette reforms will benefit the business and investment environment in Jordan. E-cigarette vendors will be attracted to investing in on-ground facilities to better liaise with the market, while the supply chain responsible for the distribution of products could also experience significant growth; traditionally, e-cigarette products are retailed by small- and medium-businesses, and the legalisation of these products with balanced taxation will attract entrepreneurs keen to set up new retail points across the country.
Through these important reforms, Jordanian authorities will also benefit from the collection of tax revenues from legally imported products. In line with this, authorities will be able to clamp down on tax evasion issues associated with illegal market players, while simultaneously working to curtail the spread of inferior and dangerous black-market products, which do not meet the standards and regulations outlined by local and international authorities. This will positively impact the safety of adult smokers who will be able to access licensed and standard-compliant e-cigarette products at an accessible price.
Links:
[1] Jordan National Stepwise Survey (STEPs) for Noncommunicable Diseases Risk Factors 2019
[2] NHS UK - Using e-cigarettes to stop smoking
[3] Tobacco Control – Potential deaths averted in USA by replacing cigarettes with e-cigarettes
Notes to Editors:
About RELX International
Founded in 2019, RELX International is a multinational electronic cigarettes company that markets and sells RELX, The world’s advanced vape brand powered by SuperSmoothTM technology. RELX, Asia’s leading e-cigarette brand, is widening its footprint across the world, and is currently available in 40+ countries such as the UK, France, Italy, Germany, Indonesia, Philippines, Canada, KSA and the UAE. What sets RELX apart from competition is the fact that it has a full ecosystem (such as closed pods, disposables, device, and power bank accessories) that are designed at a cutting-edge research and development center and produced at one of the world’s largest e-cigarette factories. RELX's mission is to make RELX a trusted brand for legal age adult smokers through state-of-the-art products, industry-leading technologies, and scientific advances in collaboration with talented and committed people around the globe. The company has attracted global talents from Uber, Procter & Gamble, Apple, Beats, and L'Oréal. RELX is proud to be listed in Dubai Duty Free, the first duty free channel in the world.
RELX's Social Media
LinkedIn: RELX International
Instagram: @RELXArabia
Facebook: @RELXArabia
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005655/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release
Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release
Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release
4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
